Celgene Corp (CELG)

110.60
3.41 2.99
NASDAQ : Health Care
Prev Close 114.01
Open 113.86
Day Low/High 110.07 / 115.50
52 Wk Low/High 92.98 / 128.39
Volume 4.75M
Avg Volume 4.58M
Exchange NASDAQ
Shares Outstanding 775.11M
Market Cap 88.52B
EPS 2.00
P/E Ratio 47.98
Div & Yield N.A. (N.A)

Latest News

Crude Selloff, Health Care Rally Split Wall Street

Crude Selloff, Health Care Rally Split Wall Street

Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

Olympic Swimmer And Author Dara Torres Teams Up With Celgene To Launch SHOW MORE OF YOU Psoriasis Campaign

Olympic Swimmer And Author Dara Torres Teams Up With Celgene To Launch SHOW MORE OF YOU Psoriasis Campaign

Twelve-time Olympic medalist, best-selling author, host of a cable sports TV show, and mom Dara Torres dives into a very important conversation this summer as she teams up with Celgene Corporation (NASDAQ:CELG) and...

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

CMCSA, IDXX, ZTS: Jim Cramer's Views

CMCSA, IDXX, ZTS: Jim Cramer's Views

Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.

Celgene Takes Over #29 Spot From Honeywell International

Celgene Takes Over #29 Spot From Honeywell International

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Celgene Corp. has taken over the #29 spot from Honeywell International Inc , according to ETF Channel.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Jim Cramer's 'Mad Money' Recap: Why You Need a Long-Term View Past August

Jim Cramer's 'Mad Money' Recap: Why You Need a Long-Term View Past August

There's a lot out there to cheer investors, Cramer says, and August could turn out to be a better month than usual.

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Celgene Has a $125 Price Target

Celgene Has a $125 Price Target

We can see the impressive reversal in the share price

Jim Cramer -- Celgene Igniting a Rally in Biotech

Jim Cramer -- Celgene Igniting a Rally in Biotech

The biotech sector was a great short throughout the year, but that trade appears to be over, Cramer said.

Celgene (CELG) Stock Slides Amid Whistleblower Lawsuit

Celgene (CELG) Stock Slides Amid Whistleblower Lawsuit

Celgene (CELG) stock is down in pre-market trading amid allegations that it donated to charities as part of a scheme for billions of taxpayers' money.

Celgene Is Heading Even Higher -- Here's How to Trade It Now

Celgene Is Heading Even Higher -- Here's How to Trade It Now

Celgene's bullish action is leaving behind a solid foundation from which the stock can mount a new bull leg.

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

Hep C Business Slow-Down Could Hamper Bristol-Myers' Future

The company's hepatitis C drug division is expected to see losses in the second half of the year.

Celgene Beats Estimates, Raises Earnings Outlook

Celgene Beats Estimates, Raises Earnings Outlook

Celgene shares jumped as the biotech company posted top-and bottom-line beats and raised its earnings forecast for the year.

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Jim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers

Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.

Pre-Market Activity Shows Gains For Celgene (CELG)

Pre-Market Activity Shows Gains For Celgene (CELG)

Trade-Ideas LLC identified Celgene (CELG) as a pre-market leader candidate

Celgene (CELG) Stock Climbs on Q2 Earnings, Revenue Beat

Celgene (CELG) Stock Climbs on Q2 Earnings, Revenue Beat

Celgene (CELG) stock is trading higher pre-market after reporting its 2016 second quarter financial results.

Celgene Reports Second Quarter 2016 Operating And Financial Results

Celgene Reports Second Quarter 2016 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,745 million for the second quarter of 2016, a 22 percent increase from the same period in 2015.